Celltrion files IND for phase 3 trial of inhaled Covid-19 cocktail therapy
Celltrion Group (Celltrion Healthcare), a South Korean pharma company, has submitted an investigational new drug (IND) application to carry out a global phase 3 clinical trial of an inhaled Covid-19 antibody cocktail therapy made up of regdanvimab (CT-P59) and CT-P63. The late-stage clinical trial will assess the efficacy and safety of the cocktail therapy in […]